Roflumilast

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
430.6±45.0 °C at 760 mmHg

[ Melting Point ]:
158°C

[ Molecular Formula ]:
C₁₇H₁₄Cl₂F₂N₂O₃

[ Molecular Weight ]:
403.207

[ Flash Point ]:
214.2±28.7 °C

[ Exact Mass ]:
402.034943

[ PSA ]:
60.45000

[ LogP ]:
4.84

[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C

[ Index of Refraction ]:
1.604

[ Storage condition ]:
Refrigerator

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
26

[ RIDADR ]:
NONH for all modes of transport

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

BMC Clin. Pharmacol. 11 , 7, (2011)

Roflumilast is an oral, selective phosphodiesterase 4 inhibitor with anti-inflammatory effects in chronic obstructive pulmonary disease (COPD). The addition of roflumilast to long-acting bronchodilato...

β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D.

PLoS ONE 6 , e20000, (2011)

Asthma is associated with airway narrowing in response to bronchoconstricting stimuli and increased airway smooth muscle (ASM) mass. In addition, some studies have suggested impaired β-agonist induced...

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Lancet 385(9971) , 857-66, (2015)

Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids and longacting β2 agonists i...

More Articles